Is ORMP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Reviving the oral insulin program, with revenue (ttm) at $0 (clinical-stage, no product sales). The bear case rests on the dominant clinical risk is failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant clinical risk is failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Reviving the oral insulin program. The central clinical question is whether Oramed can turn ORMD-0801 into an approvable product after its Phase 3 failure in Type 2 diabetes.

The dominant clinical risk is failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product. A large part of the company's value and all of its 2026 profit come from investments and notes tied to other companies, whose marks can fall as fast as they rose; a reversal would show up as losses and a lower book value. Financing and dilution are constant concerns for clinical-stage biotech. The company's reliance on partnerships adds counterparty and execution risk, as shown when a planned joint venture was terminated after closing conditions went unmet. As a small-cap followed by a single analyst, the stock can be volatile and may move sharply on single announcements; it fell ~14% in the month to October 16, 2026. None of this is investment advice.

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on the oral delivery of drugs that normally have to be injected.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Reviving the oral insulin program) stalling in the reported numbers rather than in the narrative, the risk above (the dominant clinical risk is failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. Oramed is a speculative, clinical-stage biotech whose lead oral insulin program already failed a Phase 3 trial. The bull case rests on reviving that program, unlocking value through partnerships, or the market closing the gap between the ~$168 million market cap and a book value roughly twice that. The bear case is another clinical setback or a reversal in the investment gains that produced all of its 2026 profit. Only investors comfortable with binary, pre-revenue drug-development risk tend to hold it, and position sizing matters.

Oramed is a clinical-stage company developing oral versions of drugs that normally require injection, built around its POD (Protein Oral Delivery) technology. Its best-known candidate is ORMD-0801, an oral insulin capsule for diabetes, and it has earlier work on an oral GLP-1 and other applications. It has no approved product, so it earns no product revenue today; its recent profits have come from investment holdings.

The defining moment was a Phase 3 trial of ORMD-0801 in Type 2 diabetes that failed to meet its primary endpoints. For a company whose value was built on that single program, a failed late-stage trial resets the entire investment case, which is why the shares repriced sharply. The stock has since recovered part of the ground, rising ~81% over the year to October 16, 2026 as investment gains lifted reported earnings.